Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NexMed, a specialty CRO with a pipeline of products based on the NexACT technology, has released results from a pre-clinical study showing that Vitaros, the company’s NexACT-based alprostadil product, promoted healing of deep tissue wounds.
Subscribe to our email newsletter
Specifically, in a pig model, subjects with deep tissue wounds that were administered 200mcgs of Vitaros healed four times faster than those receiving placebo over a 21-day period. This deep-seeded, wound healing pig model is widely regarded as the gold standard for pre-clinical testing of efficacy of wound-healing treatments. Vitaros is currently in late-stage development for the treatment of erectile dysfunction.
Bassam Damaj, president and CEO of NexMed, said: “Poor blood supply is often a major factor in patients with healing failure. Alprostadil is a well known vasodilator which can enhance local microcirculation by inducing capillary dilation and neovascularization.
“The aim of our study was to test the safety and efficacy of Vitaros and its potential to promote wound healing in a long-term pre-clinical model. These initial results were very encouraging and warrant further testing of our NexACT-based alprostadil product in human clinical trials.”